Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Breast Neoplasms × Lenograstim × Breast × Clear all
NCT05296317 2026-02-19

EMEG-ECDD

Centre Georges Francois Leclerc

Phase NA Completed
97 enrolled
Breast

Breast Neoplasms

NCT00615602 2015-03-04

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Hellenic Oncology Research Group

Phase 3 Completed
489 enrolled
Breast

Breast Neoplasms

NCT01985724 2014-05-14

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Hellenic Oncology Research Group

Phase 3 Completed
650 enrolled
Breast

Breast Neoplasms

NCT00431080 2008-01-21

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Hellenic Oncology Research Group

Phase 3 Completed
478 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡